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Abstract
The HIV/AIDS epidemic continues to spread despite more than 20 years of significant research and
major advances in its treatment. The introduction of highly active antiretroviral therapy in recent
years has significantly improved disease treatment with a dramatic impact in HIV/AIDS associated
morbidity and mortality in countries which have access to this therapy. Despite these advances,
such therapies are imperfect and other therapeutic modalities, including immune-based therapies,
are being actively sought. Potential benefits of immune-based therapies include: 1) the improvement
of HIV-specific immunity to enhance control of viral replication, 2) the improvement of other
aspects of host immunity in order to prevent or delay the development of opportunistic infections
and 3) the potential to purge virus from cellular reservoirs which are sustained despite the effects
of potent antiretroviral therapy. Granulocyte-macrophage colony-stimulating factor (GM-CSF) has
been studied as one of these immune-based therapies. Several randomized, controlled trials have
demonstrated benefits of using GM-CSF as an adjunct to conventional anti-retroviral therapy,
although such benefits have not been universally observed. Individual studies have shown that GM-
CSF increases CD4+ T cells counts and may be associated with decreased plasma HIV RNA levels.
There is limited evidence that GM-CSF may help prevent the emergence of antiretroviral drug
resistant viruses and that it may decrease the risk of infection in advanced HIV disease. Despite its
high costs and the need to be administered subcutaneously, encouraging results continue to
emerge from further studies, suggesting that GM-CSF has the potential to become an effective
agent in the treatment of HIV infection.
Review
Introduction
More than 20 years after its discovery, and despite exten-
sive research in the field, HIV-1 infection remains one of
the most important public health problems in the world.
The HIV/AIDS epidemic continues to spread and an
increasing number of people continue to live with HIV/
AIDS and die from it. The advent of highly active antiret-
roviral therapy (HAART) marked a cornerstone in HIV/
AIDS treatment that drastically changed the prognosis of
HIV infection, by its ability to induce sustained suppres-
sion of viral replication [1-4]. Yet HIV infection remains,
to this day, incurable. Even with multiple available thera-
peutic options, failure of therapy, manifested by a
rebound in plasma viral load accompanied by further
decline in CD4+ T cell counts, remains frequent, leaving
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limited available options for the treatment of individuals
experiencing such failures. The persistence of HIV infec-
tion in the face of HAART is due to its limited effect on the
persistent cellular reservoir(s) of replication-competent
virus. T cells and macrophages have been implicated as
such reservoirs [5-7]. This discovery prompted research in
the field of immune-based therapy, in the hopes of
enhancing or restoring cell mediated immune responses
to HIV, or even purging latent viral reservoirs. A number
of different approaches have been and are being studied,
including several cytokines and therapeutic vaccines that
are at various stages of evaluation in human trials [8-10].
Only a limited numbers of these have however been eval-
uated in controlled clinical trials and only interleukin-2
(IL-2), Remune™ and GM-CSF have been the subject of
phase III studies, with clinical events as the primary out-
comes [11-14]. Initially used in the treatment of leukope-
nia in HIV-1 infection, GM-CSF has also been used in
clinical trials as an adjunct to HAART in which some of
the results appear promising [12,15-18]. In this review,
results from published randomized controlled trials that
have evaluated the potential role for GM-CSF in the man-
agement of patients with HIV infection will be summa-
rized (see Table in Additional file: 1).
Pre clinical and early clinical studies and the rationale for 
GM-CSF as an adjunctive treatment in HIV infection
GM-CSF is a pleiotropic growth factor that enhances the
number and function of various cells from both the mye-
loid and lymphoid lineages, including neutrophils,
monocytes and lymphocytes [19]. It is one of the many
cytokines profoundly affected by HIV infection with its
production being significantly reduced [20,21]. This has
been one of several rationales for its use in HIV-infection.
First, replacement therapy is seen as a way of enhancing
the bone marrow's production of cells important in cell-
mediated immunity, including CD4+ lymphocytes. Sec-
ond, GM-CSF has also been shown in vitro to enhance the
activity of the antiretroviral agent zidovudine (AZT) in
macrophages [22,23] and thus may be an approach to
enhance clearance of viral reservoir when used in combi-
nation with HAART. Third, GM-CSF also has an effect on
monocyte-derived macrophages. Maturation of mono-
cytes into macrophages is usually accompanied by an
increase in the expression of CCR5, the co-receptor for the
M-tropic HIV strains, a finding that seems to explain the
observation that HIV entry is more efficient in macro-
phages than in monocytes [24]. In vitro, the presence of
GM-CSF suppresses the expression of CXCR4 mRNA and
CCR5 mRNA by monocytes differentiating in macro-
phages, resulting in macrophages that are relatively resist-
ant to M-tropic HIV infection [25].
In addition to in vitro studies that have suggested that GM-
CSF enhances the action of anti-retroviral drugs (ARVD)
in macrophages [22,23], data supports the idea that GM-
CSF can also lower the frequency of ARVD-resistant HIV-
1 mutants in vivo. There appears to be lower frequency of
resistant-mutations among subjects on zidovudine and
GM-CSF, as part of their anti-retroviral regimens, versus
those on AZT alone [16]. This finding is of potential sig-
nificance, as the management of drug resistant strains of
HIV remains a major issue. However, which specific muta-
tions were observed at what frequency was not reported.
This has an impact on the importance of this finding, as
not all mutations have the same clinical significance. As
well, whether these observations with AZT occur with
other ARVD and how relevant this is given the current
management of HIV-infected individuals remains to be
established. Although it is used effectively in patients with
neutropenia, typically caused by medication or bone mar-
row dysfunction [26-28], the positive effect of GM-CSF on
CD4+ lymphocyte count in HIV had not been studied or
well documented in early observational studies [29-31].
Following these in vitro findings and early in vivo studies,
several randomized controlled trials were developed that
studied the effect of GM-CSF as a treatment for HIV-1
infected individuals.
Impact of GM-CSF use in HIV infected individuals
Effect of GM-CSF on plasma HIV RNA levels
Few randomized controlled trials of GM-CSF have shown
a clear, significant reduction in HIV replication. The first
randomized controlled trial on the use of GM-CSF in non-
neutropenic HIV-1 infected subjects, published in 1999,
did not show any significant effect of GM-CSF on plasma
HIV RNA levels [15]. This trial enrolled 20 patients, ten in
the placebo group and ten in the treatment group. Sub-
jects had similar baseline characteristics; the mean HIV
RNA load was 3.95 log10 copies/ml in the placebo group
compared with 4.21 log10 in the treatment group (p =
0.29) and the mean CD4+ T cells count in the placebo
group was 243 cells/mm3 compared with 178 cells/mm3
in the GM-CSF group. All subjects were on stable antiret-
roviral therapy, including either indinavir or ritonavir, for
a mean period of 5.0 months in the placebo group and 4.8
months in the treatment group. They received either 250
µg of GM-CSF or placebo subcutaneously 3 times per
week for a total of eight weeks. All subjects were followed
closely every two weeks during the study and twice at
week 3 and week 5 after the study ended. During the study
and at both follow up time points, the viral load remained
within 0.5 log10 copies/ml of the baseline values for both
groups.
Despite no overall changes in the mean HIV RNA load
between groups, more subjects in the GM-CSF group than
in the control group had HIV RNA values decreased by
>0.5 log10 from baseline (50% vs. 10%). Since this size of
a viral load decrease has been associated with clinical ben-Journal of Immune Based Therapies and Vaccines 2005, 3:3 http://www.jibtherapies.com/content/3/1/3
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efits, this study suggests that GM-CSF may have a benefi-
cial effect in a subset of individuals.
In the largest double blind, randomized controlled trial
on GM-CSF use in HIV infected individuals published to
date, 309 subjects stratified according to viral load (≤
30000 copies/ml vs. > 30000 copies/ml) received either
250 µg of GM-CSF or placebo three times per week for 24
weeks [12]. In total, 70% of subjects completed the full
24-week period. In the treatment and control arm respec-
tively, 89 and 90% were males, 80% and 79% of subjects
were on at least 3 antiretroviral agents, and 82% in both
groups previously had one or more opportunistic infec-
tion. The mean CD4+ T cell count was 49.8 cells/mm3 in
the control group and 50.8 cells/mm3 in the GM-CSF
group. The majority of subjects entered the study with a
viral load over 30000 copies/ml (62% for the placebo arm
and 63% for the GM-CSF arm). There was no significant
decrease in HIV-RNA in the combined strata in either the
placebo or treatment group. However, GM-CSF had a pos-
itive influence on other viral parameters. GM-CSF use
delayed virologic failure in those patients with plasma
HIV RNA levels less than 400 copies/ml before initiation
of GM-CSF therapy. At 6 months, 24 out of 29 (83%) of
subjects on GM-CSF maintained viral loads below the
limit of detection compared to 15 out of 28 (54%) of
those on placebo (p = 0.02). This, in turn, reduced the
need for antiretroviral regimen change. In this trial, ARVD
regimen changes were allowed, which could have
obscured a preferential decrease in viral load by GM-CSF.
As such, there were fewer changes in ARVD regimens in
the GM-CSF group (19%) than in the placebo group
(38%) for the lower viral load stratum (p = 0.03). In the
higher stratum, no significant difference in treatment
change was observed (62% placebo versus 62% GM-CSF;
p = 0.68). Again, this supports the idea that low-dose GM-
CSF may have the potential to limit HIV replication and
prevent or delay the development of drug resistant viruses,
as described earlier in in vitro and in vivo studies.
In a Brazilian study, 105 individuals with AIDS were
enrolled in a placebo-controlled, double-blind rand-
omized control trial to receive AZT along with GM-CSF
(125 µg) or placebo twice weekly for 6 months [16]. Sub-
jects were required to have an AIDS defining diagnosis
based on 1993 Center for Disease Control and Prevention
criteria within the last three months or a CD4+ cell count
<300 cells/mm3. Patients were excluded if they had an
active AIDS defining diagnosis at the time of randomiza-
tion or if they had been exposed to zidovudine for >6
months prior to study entry. The mean HIV RNA plasma
levels at baseline were 93000 copies/ml in the placebo
group and 155000 copies/ml in the GM-CSF group (p =
0.21). All the subjects received AZT, and 65% and 68% of
subjects in the placebo and GM-CSF group respectively
were also on a second agent, either ddI, ddC, 3TC or
Saquinavir. Prior opportunistic infection rates were 58%
in the placebo group and 70% in the treatment group (p
= 0.14). This study did show a statistically significant
effect of GM-CSF on viral loads. Mean HIV RNA levels
declined in the GM-CSF group throughout the 6 months
of the study. Over this period, the change was -0.07 log10
copies/ml in the control group as opposed to -0.60
log10copies/ml in the treatment group (95% CI -0.94-
0.12; p = 0.02). As well, there was a greater number of sub-
jects in the GM-CSF group with a decrease of 1 log10 or
greater in viral load (20/52; 38%) compared with the pla-
cebo group (9/53; 17%) (p = 0.02). The reason why a
decrease in viral load was observed in this study and not
in other trials is unclear. It was the only trial with a smaller
dose of GM-CSF (125 µg twice weekly vs. 250 µg thrice
weekly for most other trials) and all patients were receiv-
ing AZT, both of which might have played a role in this
difference.
More recent clinical data on the use of GM-CSF in combi-
nation with HAART continues to show some effect of GM-
CSF on viral load [17]. These data stem from a rand-
omized controlled trial in which 116 subjects were
required to remained virologically stable (within a differ-
ence of 0.7 log10 copies/ml) for at least 7 days prior to
entry and where no HAART regimen change was allowed
during the 16 weeks period of the trial. Subjects were
divided in 2 groups, depending if their CD4+ T count was
below or above 200 cells/mm3 at baseline and then rand-
omized to either 250 ug of GM-CSF or placebo three times
per week for 16 weeks. All patients subsequently received
a 32-week course of open label GM-CSF. Baseline charac-
teristics were similar in both groups. At baseline, in the ≥
200 and <200 CD4+ cells/mm3 strata, median plasma
RNA levels were 3.81 log10 and 4.46 log10 copies/ml, with
no difference between control and treatment groups. After
the 16 weeks of double-blinded treatment, the change in
HIV RNA levels was +0.048 log10 copies/ml in the GM-
CSF group compared with -0.103 log10 copies/ml (p =
0.036) in the placebo group, both strata combined. How-
ever, when the two strata (≥  200 and <200 CD4+ cells/
mm3) were studied individually, the changes in mean
viral loads were not significant. Thus, in this trial, subjects
in the GM-CSF group, irrespective of their initial CD4+
count, tended to have a modest increase in HIV RNA lev-
els at the end of the 16-week randomized period.
Although the modest increase in viral load was significant,
it was not associated with a decrease in CD4 counts or an
increase in clinical events, as is discussed later.
Finally, a Swiss study evaluated the use of GM-CSF 300 µg
three times a week for the first four weeks of a 12-week
HAART interruption period [18]. This small study rand-
omized 33 subjects who had previously been stable onJournal of Immune Based Therapies and Vaccines 2005, 3:3 http://www.jibtherapies.com/content/3/1/3
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HAART for at least six months, with viral load below 50
copies/ml and CD4+ T cell counts >400 cells/mm3. In
both groups the viral load peaked at 6 weeks and trended
down afterwards. In the GM-CSF group, the maximum
viral load reached a mean of 4.97 log10 compared with
5.54 log10 in the scheduled treatment interruption-only
(STI-only) group (p = 0.03). Over a period of twelve
weeks, the mean area under the curve for viral loads were
47.77 log10 in the GM-CSF group and 51.88 log10 in the
STI-only group (p = 0.07) This suggests not only that there
is no deleterious effect of GM-CSF on plasma HIV RNA
levels but that GM-CSF may help control the viral load in
patients who need to stop HAART for a short period.
Overall, the evidence regarding the effect of GM-CSF on
plasma HIV-1 RNA levels is somewhat conflicting. Four of
the five trials reviewed show either a significant decline or
no statistical changes in the viral load. The explanation for
the observed increase in viral load in the GM-CSF group
in the trial by Jacobson et al. is not clear. This study was
somewhat unique in that it included only patients with
uncontrolled viral replication. It appears likely that the
impact of GM-CSF on viral load is dependant upon the
setting in which GM-CSF is used. Furthermore, GM-CSF
may selectively enhance the antiviral activity of specific
antiretroviral agents (e.g. AZT). Also, as may be becoming
apparent with other immune-based therapies, the greatest
effect of GM-CSF may be observed in situations where
there is the greatest degree of virologic suppression and
associated immunologic recovery.
Effect of GM-CSF on CD4+ T cells
The initial randomized control trial of GM-CSF use in
non-leukopenic HIV infected individuals, referred to pre-
viously, reported other important findings. CD4+ T cell
counts reached higher levels in the treatment group, but
these results did not reach statistical significance [15]. The
mean maximal increase in the treatment group was 129.6
± 149.9 cells/mm3 and 57 ± 58.9 cells/mm3 in the control
group (p = 0.02). A significant majority (70%) of subjects
treated with GM-CSF demonstrated an increase of >30%
of their CD4+ T cell counts over baseline at any given time
versus a minority (30%) in the placebo group (p = 0.07).
When those patients with baseline CD4+ T cell counts of
<50 cells/mm3 were excluded from the analysis, in order
to ensure an increase of >30% was not due to daily varia-
bility, 6 of 7 patients in the GM-CSF group and 1 of 8
patients in the placebo group had a CD4+ T cell increase
of >30% (p = 0.01). This may have a clinical impact as a
>30% increase of the CD4+ T cell count in light of a stable
viral load has been associated with a relative risk reduc-
tion of disease progression in a previous study [32].
An earlier randomized controlled study looking into the
effect of GM-CSF on leukopenia in HIV-infected individu-
als also demonstrated an increase in CD4+ T cell counts.
After 12 weeks of therapy (300 µg GM-CSF daily for 1
week then 150 µg twice-a-week for 11 weeks), absolute
CD4+ T cell counts rose by 53% compared to baseline (p
< 0.001) and was statistically different than that observed
in the control group (p < 0.001) [26].
Other trials observed a trend towards modest, non-signif-
icant, increases in the absolute CD4+ counts. In the study
by Brites et al, the authors reported a modest increase in
the CD4+ T cell count in both groups at six months [16].
In the GM-CSF group, there was a small, non-significant
increase in the CD4+ T cell count of 35 cells/mm3 com-
pared with 12 cells/mm3 in placebo group (p = 0.42). As
with the study by Skowron et al, they also observed a sig-
nificant difference in the number of subjects who had a ≥
30% increase of the CD4+ T cell count. Only 59% of sub-
jects in the placebo group achieved this increase as
opposed to 80% in the GM-CSF group (p = 0.03).
In the other, more recent trial, from Jacobson et al., the
authors reported a change in the CD4+ T cell count of +29
cells/mm3 in the GM-CSF vs. -8 cells/mm3 in the placebo
group for the stratum of subjects with >200 CD4+ T cells/
mm3 at baseline (p = .20) [17]. They observed a similar
trend in the <200 CD4+ T cells/mm3 stratum, with +5
cells/mm3 in the GM-CSF group at 16 weeks vs. -5 cells/
mm3 in the placebo group but this did not reach statistical
significance (p = 0.22).
Fairly convincing evidence of a significant increase in
absolute CD4+ leukocyte count following treatment with
GM-CSF comes from the phase III randomized control
trial by Angel and colleagues, described earlier [12]. The
baseline CD4+ T counts were 49.8 × 106 cells/L for the pla-
cebo group and 50.8 × 106 cells/L for the treatment group.
At 12 months the mean CD4+ T cell count was 102 ± 15 ×
106 cells/L in the placebo group vs. 152 ± 18 × 106 cells/L
in the treatment group. This was also reflected by statisti-
cally significantly greater increases in the CD4+ T cell
count at 1, 3 and 6 months in the GM-CSF group.
It might be speculated that, since this was the largest (n =
307) and one of the longest (24 weeks) randomized con-
trol trial of GM-CSF use in HIV infected individuals, it
maybe the only study with enough power to demonstrate
statistical significance. As other randomized control trials
show trends towards higher CD4+ T cell counts in the
GM-CSF group, and statistically significant difference in
various sub-analysis, it is possible that an appropriately
conducted meta-analysis would clarify the impact of GM-
CSF on CD4+ T cell counts.
The recent study by the Swiss group also supports a posi-
tive effect of GM-CSF on CD4+ lymphocytes count [18].Journal of Immune Based Therapies and Vaccines 2005, 3:3 http://www.jibtherapies.com/content/3/1/3
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In that trial, the CD4+ T cell counts fell from 720 × 106
cells/L at baseline to 537 × 106 cells/L at four weeks after
stopping HAART in the STI-only group (p < 0.001). In the
GM-CSF treated group, there was no significant change in
the CD4+ T cell counts four weeks after stopping HAART.
CD4+ T cell counts were 890 × 106 cells/L at baseline and
792 × 106 cells/L at week four (p = 0.6). This adds evidence
that GM-CSF could have a beneficial effect on CD4+ T cell
counts.
Impact of GM-CSF on clinical outcomes
GM-CSF has an excellent safety and tolerability profile
when used in HIV-1 infected individuals [12,15-17]. In all
the major randomized controlled trial, pain, local swell-
ing and erythema were the most frequent side effects and
reactions were almost all grade 1 or 2 with only rare grade
3 or 4 events. In the recent randomized controlled trial by
Jacobson et al, a total of 4 patients had to discontinue GM-
CSF use because of toxicity or acute allergic reactions [17].
That was not the case in other trials, where there were no
discontinuations of therapy over many patient-months of
therapy [12,15,16]. There were no hospitalizations or
death attributable to GM-CSF in any study.
The large phase III trial by Angel et al. has been the only
study to use clinical events as endpoints, using the Centers
for Diseases Control and Prevention definition of oppor-
tunistic infections (OI), bacterial pneumonia or death as
their primary endpoint [12]. An effect of GM-CSF on the
rate of OI was not observed, with an event rate of 18% in
the placebo group and 21% in the GM-CSF group (p =
0.61). Despite this, there were some important benefits to
the use of GM-CSF on other clinical events. These same
authors found that the incidence of overall infections (OI
and non-OI) was significantly lower in the treatment
group of their study; 78% in the placebo group versus
67% in the GM-CSF group (p = 0.03). They also found
that time to occurrence of the first infection or death was
also significantly longer when GM-CSF was used as an
adjunctive treatment in HIV infection (97 days vs. 56 days
for placebo; p = 0.04).
For individuals who do not have a history of OI, GM-CSF
may decrease the risk of a first opportunistic infec-
tion[16]. Despite the fact that they did not observe differ-
ences in the rate of overall infections or OI, Brites et al. did
noticed that all 17 subjects in the GM-CSF arm who devel-
oped an OI had a prior history of one or more of these
infections. In the placebo group, only 50% of the 14 sub-
jects who developed an OI during the study had a prior
history of OI (p < 0.01). This might prove to be an impor-
tant role for adjunct treatment with GM-CSF as OI are still
an important cause of morbidity and mortality in HIV
infected individuals.
The most recent randomized control trail by Jacobson et
al. did show a non-significant reduction in clinical events
in the GM-CSF group [17]. No HIV associated clinical
events were seen in the treatment group versus 4 in the
placebo group (p = 0.12), Again, all the subjects in this
trial were on stable HAART prior to and during the study,
which is likely responsible for a very low incidence of
both overall and OI rates. This, combined with a smaller
sample size, likely accounts for the lack of power of this
trial to demonstrate an effect of GM-CSF on clinical
events.
Finally, the study by Fagard et al. failed to show any
impact of GM-CSF on clinical events during HAART inter-
ruption. However, they studied only 33 patients with high
CD4 counts and off HAART for a limited period of time
[18].
Despite all these results, questions still remain as to
whether use of GM-CSF is associated with a reduction in
the incidence of AIDS related morbidity and mortality, as
even the authors of the largest phase III study published
to date admit to a lack of power in their trial [12]. The
introduction of HAART at the time of this trial, thereby
likely lowering the incidence of OI in both the GM-CSF
group and placebo group, could be expected to have had
a significant impact on the outcome of that study.
Conclusion
In various studies GM-CSF has a positive effect on impor-
tant parameters of HIV infection, namely plasma HIV
RNA levels and CD4+ lymphocytes counts. Although the
positive effects are modest and not universally observed,
they are significant in many trials. Moreover, the positive
effect on these measures may translate into significant
clinical benefits. Clinical outcome results of current rand-
omized controlled trials are, thus far, somewhat encourag-
ing. Despite the frequent lack of statistical significance,
there are positive trends towards clinical benefit of GM-
CSF use in these studies. Moreover, the largest rand-
omized control trial did show that GM-CSF produces a
significant reduction in the time to first infection or death.
The possibility of allowing longer disease free periods is a
desirable outcome for HIV infected individuals, contribut-
ing to improved quality of life. However, the high cost of
GM-CSF and its mode of administration may be difficult
hurdles for patients to overcome.
Future trials designed to look at specific clinical outcomes,
for example diseases free period, progression of HIV infec-
tion and quality of life, might bring to light additional
beneficial effects of GM-CSF. This would require focusing
on patients with advanced HIV disease and lower CD4
counts. Alternatively, future trials could focus on the use
of GM-CSF as an adjuvant therapy, either to HAART or asJournal of Immune Based Therapies and Vaccines 2005, 3:3 http://www.jibtherapies.com/content/3/1/3
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an adjuvant with HIV or other vaccines. There is growing
evidence that GM-CSF enhances the immune response to
vaccines directed against both infectious agents and vari-
ous cancers [33]. Clinical trials of GM-CSF as an adjuvant
to hepatitis B vaccination have shown some positive
results [34-37]. Moreover, GM-CSF when added as an
adjuvant to HIV envelope vaccination in mice resulted in
a greater HIV-specific cellular immune response [38].
Regardless of future studies, it would appear important
that those trials focus on individuals with suppressed viral
replication, as they seem more likely to realize the benefits
of GM-CSF.
It remains to be seen if GM-CSF will ever loose its experi-
mental status and become an accepted therapy for
selected individuals HIV infection. The evidence for the
role of immunotherapy in HIV/AIDS is ever increasing
and GM-CSF might very well become a widely accepted
treatment in the years to come.
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